-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on 10x Genomics, Lowers Price Target to $70

Benzinga·11/09/2026 15:18:35
Listen to the news
Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and lowers the price target from $110 to $70.